Assessment of PBC Pruritus From the ITCH ‐E Study: Quality of Life, Productivity, and Treatment Experiences
Liver International · 2025
DOI: 10.1111/liv.70276 ↗Kurz gefasst
Fachartikel in der Zeitschrift Liver International, 2025. Verfasst von Cynthia Levy und 9 weiteren Autor:innen. Beteiligte Einrichtung: Schiff Center for Liver Diseases, University of Miami, Miami, Florida, USA. Hauptthemen laut MEDLINE: Quality of Life, Pruritus, Liver Cirrhosis, Biliary, Efficiency. Die Arbeit wurde bisher 10-mal zitiert (Crossref) und nennt 41 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC-ND 4.0). Gefördert von: Gilead Sciences.
Abstract (Originalsprache)
Background & Aims This US‐based study assessed the impact of pruritus on health‐related quality of life (HRQoL) and treatment experiences of people with primary biliary cholangitis (PBC).
Methods
Patients with PBC were recruited from a physician panel and patient advocacy group. Participants were grouped by the Pruritus Numerical Rating Scale (NRS): No/Mild Pruritus (NMP, NRS < 4) and Moderate/Severe Pruritus (MSP, NRS ≥ 4). Participants completed the 5‐D Itch, PBC‐40, EQ‐5D‐5L, Chronic Liver Disease Questionnaire (CLDQ‐PBC), Work Productivity and Activity Impairment (WPAI), and Functional Assessment of Chronic Illness Therapy – Fatigue Scale, Version 4 (FACIT‐Fatigue) questionnaires, and PBC treatment experiences questions. Differences were analysed using regression models for confounders. An MSP group subset responded to voice questions.
Results
The sample included 40 NMP and 50 MSP participants, with 85% and 80% females, respectively. The MSP group reported significantly worse outcomes on 5‐D Itch, EQ‐5D Index, PBC‐40 (all domains besides Emotional), FACIT‐Fatigue, and CLDQ‐PBC total scores compared to the NMP group (all p < 0.05). The MSP group reported significantly greater activity impairment due to PBC (57%) than the NMP group (36%; p < 0.001). The MSP group had a lower employment rate (42%) than the NMP group (53%). Fewer than 25% of the MSP group were receiving itch treatment.
Conclusions
Individuals with PBC and pruritus report limited pruritus treatment use and minimal itch relief. Those with moderate/severe pruritus experience a greater HRQoL burden and reduced activity compared to those with mild/no pruritus. This highlights the need for effective treatments that ameliorate pruritus in patients with PBC.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Autor:innen und Institutionen
- Schiff Center for Liver Diseases, University of Miami, Miami, Florida, USA.
- The Global Liver Council, Washington, DC, USA.
- Beatty Liver and Obesity Research, Inova Health System, Falls Church, Virginia, USA.
- Division of Digestive and Liver Diseases, University of Texas Southwestern Medical Center, Dallas, Texas, USA.
- Department of Gastroenterology and Hepatology, University Hospital Zürich, University of Zürich, Zürich, Switzerland.
- Independent Researcher, Sugar Land, Texas, USA.
ORCID-Profile: Zobair M Younossi, Andreas E Kremer, Brad Padilla
Förderung
- Gilead Sciences
Zitieren
APA
Levy, C., Younossi, Z. M., Mayo, M. J., Kremer, A. E., Pate, J., Ieyoub, J., Zincavage, R., Padilla, B., Ito, D., & Perez, C. F. M. (2025). Assessment of PBC Pruritus From the ITCH ‐E Study: Quality of Life, Productivity, and Treatment Experiences. Liver International. https://doi.org/10.1111/liv.70276
Vancouver
Levy C, Younossi ZM, Mayo MJ, Kremer AE, Pate J, Ieyoub J, et al. Assessment of PBC Pruritus From the ITCH ‐E Study: Quality of Life, Productivity, and Treatment Experiences. Liver International. 2025. doi:10.1111/liv.70276
BibTeX
@article{Levy2025,
author = {Levy, Cynthia and Younossi, Zobair M and Mayo, Marlyn J and Kremer, Andreas E and Pate, Jennifer and Ieyoub, Jonathan and Zincavage, Rebekah and Padilla, Brad and Ito, Diane and Perez, C Fiorella Murillo},
title = {Assessment of PBC Pruritus From the ITCH ‐E Study: Quality of Life, Productivity, and Treatment Experiences},
journal = {Liver International},
year = {2025},
doi = {10.1111/liv.70276}
}
EUVIMED